S&P 500   2,991.63 (-0.21%)
DOW   26,939.33 (-0.32%)
QQQ   192.56 (-0.44%)
AAPL   235.48 (+0.49%)
FB   187.98 (-0.89%)
MSFT   138.29 (-0.85%)
GOOGL   1,251.99 (-0.15%)
AMZN   1,772.45 (-1.00%)
CGC   20.19 (-0.59%)
NVDA   192.10 (-0.26%)
MU   44.19 (-2.75%)
BABA   172.55 (-2.09%)
GE   8.99 (-0.88%)
TSLA   259.34 (-1.17%)
AMD   30.89 (-0.39%)
T   38.03 (+0.66%)
F   9.24 (+1.65%)
ACB   3.72 (-2.11%)
PRI   124.25 (+0.23%)
NFLX   278.87 (-4.94%)
BAC   30.23 (+0.53%)
GILD   64.70 (-0.72%)
S&P 500   2,991.63 (-0.21%)
DOW   26,939.33 (-0.32%)
QQQ   192.56 (-0.44%)
AAPL   235.48 (+0.49%)
FB   187.98 (-0.89%)
MSFT   138.29 (-0.85%)
GOOGL   1,251.99 (-0.15%)
AMZN   1,772.45 (-1.00%)
CGC   20.19 (-0.59%)
NVDA   192.10 (-0.26%)
MU   44.19 (-2.75%)
BABA   172.55 (-2.09%)
GE   8.99 (-0.88%)
TSLA   259.34 (-1.17%)
AMD   30.89 (-0.39%)
T   38.03 (+0.66%)
F   9.24 (+1.65%)
ACB   3.72 (-2.11%)
PRI   124.25 (+0.23%)
NFLX   278.87 (-4.94%)
BAC   30.23 (+0.53%)
GILD   64.70 (-0.72%)
Log in

Cidara Therapeutics Stock Price, News & Analysis (NASDAQ:CDTX)

$1.91
-0.03 (-1.55 %)
(As of 10/18/2019 11:06 AM ET)
Today's Range
$1.91
Now: $1.91
$1.95
50-Day Range
$1.54
MA: $1.95
$2.78
52-Week Range
$1.22
Now: $1.91
$4.44
Volume4,117 shs
Average Volume165,948 shs
Market Capitalization$51.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDTX
CUSIPN/A
Phone858-752-6170

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.13 per share

Profitability

Net Income$-59,020,000.00

Miscellaneous

Employees68
Market Cap$51.13 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.


Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics Inc (NASDAQ:CDTX) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.06. View Cidara Therapeutics' Earnings History.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Cidara Therapeutics.

What price target have analysts set for CDTX?

5 Wall Street analysts have issued twelve-month price targets for Cidara Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Cidara Therapeutics' share price to reach $7.00 in the next year. This suggests a possible upside of 266.5% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics.

What is the consensus analysts' recommendation for Cidara Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics.

What are Wall Street analysts saying about Cidara Therapeutics stock?

Here are some recent quotes from research analysts about Cidara Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (8/21/2019)
  • 2. Cantor Fitzgerald analysts commented, "CDTX’s pipeline is focused on better ways to treat fungal and bacterial infections as well as influenza. We expect pipeline advancements to drive upwards earnings revisions to levels not yet reflected in the consensus. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $15." (4/15/2019)

Has Cidara Therapeutics been receiving favorable news coverage?

News stories about CDTX stock have trended neutral on Friday, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cidara Therapeutics earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cidara Therapeutics.

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,590,000 shares, an increase of 22.3% from the August 30th total of 1,300,000 shares. Based on an average trading volume of 464,900 shares, the days-to-cover ratio is presently 3.4 days. Approximately 11.7% of the company's shares are short sold. View Cidara Therapeutics' Current Options Chain.

Who are some of Cidara Therapeutics' key competitors?

What other stocks do shareholders of Cidara Therapeutics own?

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the folowing people:
  • Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 64)
  • Dr. Taylor Sandison, Chief Medical Officer (Age 47)
  • Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 42)
  • Mr. James E. Levine, Chief Financial Officer (Age 48)
  • Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 50)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $1.91.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $51.13 million. The biotechnology company earns $-59,020,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.View Additional Information About Cidara Therapeutics.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is http://www.cidara.com/.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]


MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  340 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  597
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe CDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel